On the Topic of Topicals: New Treatment Options for Plaque Psoriasis (Online CME/CE Monograph)
Activity Description and Purpose
The armamentarium for topical treatment of plaque psoriasis was expanded in 2022 with US Food and Drug Administration approval of 2 nonsteroidal products: tapinarof, 1.0%, cream and roflumilast, 0.3%, cream. Both of these medications are first-in-class topical treatments for plaque psoriasis. Results from clinical trials investigating their safety, efficacy, and tolerability indicate they have features that are important for overcoming the drawbacks of established topical therapies. This educational activity presents information on the mechanism of action of the new nonsteroidal agents, evidence from their premarketing clinical trials, and expert insights on their use in clinical practice. The desired results of this educational activity are for dermatologists and dermatology advanced practice providers to gain knowledge of the newest mechanism of action in psoriasis treatment—aryl hydrocarbon activation—and to review the mechanism of phosphodiesterase-4 inhibition in psoriasis treatment.
This educational activity is intended for dermatologists and dermatology advanced practice providers, including nurses, nurse practitioners, and physician assistants.
After completing this activity, participants will be better able to:
- Review clinical efficacy and safety of new topical treatments for plaque psoriasis
- Describe the mechanism of action of aryl hydrocarbon receptor agonism in the treatment of plaque psoriasis
- Identify strategies to overcome barriers to poor adherence to topical treatments for plaque psoriasis
- Apply evidence for topical therapies to individualize treatment for the long-term management of plaque psoriasis
Linda Stein Gold, MD
Bruce Strober, MD, PhD, FAAD
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
George Martin, MD, is a consultant for AbbVie Inc, Almirall, SA, Bausch & Lomb Incorporated, Bristol-Myers Squibb, Celgene Corporation, DUSA Pharmaceuticals, Eli Lilly and Company, Evelo Biosciences, Inc, Galderma, LEO Pharma, Ortho Dermatologics, Pfizer Inc, Sun Pharmaceutical Industries, Inc, Trevi Therapeutics, and UCB SA; is an advisory board member of AbbVie Inc, Almirall, SA, Bausch & Lomb Incorporated, Bristol-Myers Squibb, Celgene Corporation, DUSA Pharmaceuticals, Evelo Biosciences, Inc, Galderma, Horizon Therapeutics plc, Janssen Pharmaceuticals, Inc, LEO Pharma, Organogenesis Inc, Ortho Dermatologics, Pfizer Inc, Sun Pharmaceutical Industries, Inc, Trevi Therapeutics, and UCB SA; and is on the speakers bureau for Almirall, SA, Dermavant Sciences, Inc, Incyte, LEO Pharma, and UCB SA.
Linda Stein Gold, MD, is a consultant for Arcutis Biotherapeutics, Inc, Dermavant Sciences, Inc, EPI Health, LLC, LEO Pharma, and Ortho Dermatologics; is on the speakers bureau for Arcutis Biotherapeutics, Inc, Dermavant Sciences, Inc, and LEO Pharma; and is a contracted researcher for Arcutis Biotherapeutics, Inc, Dermavant Sciences, Inc, and LEO Pharma.
Bruce Strober, MD, PhD, is a consultant for AbbVie Inc, Alamar Biosciences, Inc, Almirall, SA, Alumis Inc, Amgen Inc, Arcutis Biotherapeutics, Inc, Arena Pharmaceuticals, Inc, Aristea Therapeutics, Asana BioSciences, LLC, Boehringer Ingelheim International GmbH, Bristol-Myers-Squibb, Connect Biopharma, CorEvitas, LLC, Dermavant Sciences, Inc, Eli Lilly and Company, Evelo Biosciences, Inc, Immunic Therapeutics, Janssen Pharmaceuticals, Inc, Kangpu, LEO Pharma, Maruho Co, Ltd, Meiji Holdings Co, Ltd, Mindera Health, Nimbus Therapeutics, Novartis Pharmaceuticals Corporation, Pfizer Inc, Protagonist Therapeutics Inc, Regeneron Pharmaceuticals, Inc, Sanofi, Sun Pharmaceutical Industries, Inc, UCB SA, Union Therapeutics A/S, Ventyx Biosciences, Inc, and VTV Therapeutics; is on the speakers bureau for AbbVie Inc, Arcutis Biotherapeutics, Inc, Dermavant Sciences, Inc, Eli Lilly and Company, Incyte, Janssen Pharmaceuticals, Inc, Regeneron Pharamceuticals, Inc, and Sanofi; is a contracted researcher for CorEvitas, LLC; has stocks or stock options in Connect Biopharma; and has stock options that have not been exercised in Mindera Health.
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
Carrie Allen, PharmD, BCPP, BCPS, MedEdicus Content Manager for this activity, was previously employed by CVS within the past 2 years, but that relationship has ended.
Medical Writer: Cheryl Guttman Krader has individual stocks in Johnson & Johnson Vision Care, Inc.
Other MedEdicus and Amedco planners, managers, and writers have no relevant commercial relationships to disclose.
Learners must read the monograph and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be viewed in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
ACCME Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA PRA Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Interprofessional Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by MedEdicus LLC and Amedco LLC. Amedco LLC is jointly accredited by the ACCME, the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Amedco Joint Accreditation #4008163.
Nurses (ANCC) Credit Designation
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Dermavant Sciences, Inc.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at firstname.lastname@example.org.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, Amedco LLC, or Dermavant Sciences, Inc.
©2023 MedEdicus LLC. 288
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation